These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22797386)

  • 1. Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Jul; 13(4):345-8. PubMed ID: 22797386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
    Sarris EG; Syrigos KN; Saif MW
    JOP; 2013 Jul; 14(4):395-400. PubMed ID: 23846936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
    Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Dimou AT; Syrigos KN; Saif MW
    JOP; 2011 Mar; 12(2):114-6. PubMed ID: 21386633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trials in pancreatic cancer.
    Yu E; Saif MW; Huber K
    JOP; 2014 Jul; 15(4):326-8. PubMed ID: 25076334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
    Saif MW
    JOP; 2007 Jul; 8(4):365-73. PubMed ID: 17625289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
    O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
    Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
    Gligorov J; André T; Epaud C; Culine S
    Bull Cancer; 2002 Aug; 89 Spec No():S134-44. PubMed ID: 12449045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    Ramfidis VS; Psyrri A; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):286-8. PubMed ID: 25076321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
    Saif MW
    JOP; 2008 Mar; 9(2):91-8. PubMed ID: 18326919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
    Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA
    Am J Clin Oncol; 2019 Feb; 42(2):184-189. PubMed ID: 30418178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
    Chan E; Chiorean EG; O'Dwyer PJ; Gabrail NY; Alcindor T; Potvin D; Chao R; Hurwitz H
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):355-364. PubMed ID: 29238851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    Ramfidis VS; Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2012 Jul; 13(4):358-60. PubMed ID: 22797389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    Saif MW
    JOP; 2011 Mar; 12(2):106-9. PubMed ID: 21386631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
    Junttila MR; Devasthali V; Cheng JH; Castillo J; Metcalfe C; Clermont AC; Otter DD; Chan E; Bou-Reslan H; Cao T; Forrest W; Nannini MA; French D; Carano R; Merchant M; Hoeflich KP; Singh M
    Mol Cancer Ther; 2015 Jan; 14(1):40-7. PubMed ID: 25376606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
    Saif MW
    JOP; 2006 Jul; 7(4):337-48. PubMed ID: 16832131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics in pancreatic cancer.
    Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.